A practical reference on Alpha-MSH: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-17. Anything still debated is marked as such rather than presented as settled.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Benzodiazepines are generally viewed as safe and effective for short-term use of two to four weeks, although cognitive impairment and paradoxical effects such as aggression or behavioral disinhibition can occur. According to the Government of Victoria's (Australia) Department of Health, long-term use can cause "impaired thinking or memory loss, anxiety and depression, irritability, paranoia, aggression, etc." A minority of people have paradoxical reactions after taking benzodiazepines such as worsened agitation or panic. Benzodiazepines are often prescribed for as-needed use, which is under-studied, but is most likely, probably safe and effective to the extent that it involves intermittent short-term use. Benzodiazepines are associated with an increased risk of suicide due to aggression, impulsivity, and negative withdrawal effects. Long-term use is controversial because of concerns about decreasing effectiveness, physical dependence, benzodiazepine withdrawal syndrome, and an increased risk of dementia and cancer. The elderly are at an increased risk of both short- and long-term adverse effects, and as a result, all benzodiazepines are listed in the Beers List of inappropriate medications for older adults. There is controversy concerning the safety of benzodiazepines during pregnancy. While they are not major teratogens, uncertainty remains as to whether they cause cleft palate in a small number of babies and whether neurobehavioural effects occur as a result of prenatal exposure; they are known to cause withdrawal symptoms in the newborn.
The very success of modernization encourages "utopian" hopes that all problems can be solved via the "spirit of science" that are inevitably dashed. Modern society causes unavoidable "irritations" which led to people looking backwards to "traditions" and/or a "clean" modernity where the state would attempt to solve social problems via radical means. The "demystification of the world" leads people to seek faith and self-validation either via irrational theories such as "race" and/or a charismatic leader who would revitalize society. Modernity creates a mass society that can be more easily manipulated and mobilized to ends that can be either moral or amoral. Peukert argued that starting in 1929 that the disjoint between Weimar democracy vs. the problems of "classical modernity" started to fell apart when faced with the Great Depression. Peukert maintained that the Weimar Republic was a muddled system built out of the compromises between so many different interests with for instance Weimar Coalition consisting of the left-wing SPD, the liberal DDP, and the centre-right Zentrum being the only political parties wholeheartedly committed to the Weimar republic. Other competing interests in Germany included the struggle between men vs. women, farmers vs. towns, Catholics vs. Protestants, and unions vs. business.
Around a dozen police officers, along with judge Claise, searched Kaili's apartment, where she was subsequently arrested. According to reports, Kaili did not resist but appeared "in a state of shock and confusion, crying and terrified." She was then interrogated for more than five hours. The raids also targeted locations connected to Antonio Panzeri, an Italian former MEP. During a search of his home, police found a large quantity of cash in his "well-stocked safe". Simultaneously, investigators raided the offices of the international NGO Fight Impunity, an organisation founded to promote the fight against impunity for serious human rights violations and crimes against humanity, where Panzeri served as president. As a result of the Brussels raids, police arrested several key figures, including Eva Kaili; Antonio Panzeri; Francesco Giorgi, Kaili's life partner and an adviser of the Italian MEP Andrea Cozzolino; Alexandros Kailis, Kaili's father and a former Greek politician; Luca Visentini, the general secretary of the International Trade Union Confederation (ITUC); Niccolò Figà-Talamanca, Secretary-General of the NGO No Peace Without Justice. At Panzeri's home, police reportedly found €600,000 in cash, with additional cash discovered at Kaili's father's home, his hotel room and the residence shared by Kaili and Giorgi. The total cash seized during the raids was €1.5 million. After her arrest, Kaili was detained at the Saint-Gilles Prison before being transferred to Haren Prison five days later.
Sources: en.wikipedia.org
== Extra reading == Habibullah, Mahmoud M; Mohan, Syam; Syed, Nabeel Kashan; Makeen, Hafiz A; Jamal, Qazi Mohammad Sajid; Alothaid, Hani; Bantun, Farkad; Alhazmi, Alaa; Hakamy, Ali; Kaabi, Yahia A; Samlan, Ghalia; Lohani, Mohtashim; Thangavel, Neelaveni; Al-Kasim, Mohamed Ahmed (June 2022). "Human Growth Hormone Fragment 176–191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells". Drug Design, Development and Therapy. 16: 1963–1974. doi:10.2147/DDDT.S367586. PMC 9249349. PMID 35783198.
=== Primary sources === Cross, J. P., and Buddhiman Gurung, eds. Gurkhas at War in Their Own Words: The Gurkha Experience 1939 to the Present (London: Greenhill, 2002), Masters, John (1956). Bugles and a Tiger: Viking. (autobiographical account of his service as a junior British officer in a Gurkha regiment in the years leading up to World War II) Omissi, David E. ed. Indian Voices of the Great War: Soldiers' Letters, 1914–18 (1999) Francis J Short. Stories from the British Indian Army (2015)
=== Preferred habitat === Bowfin prefer vegetated sloughs, lowland rivers and lakes, swamps, and backwater areas, and are occasionally found in brackish water. They are well camouflaged and difficult to spot in slow water with abundant vegetation. They often seek shelter under roots and submerged logs. Oxygen-poor environments can be tolerated because of their ability to breathe air.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.